Understanding the Investigation into uniQure N.V.
The law firm of Kirby McInerney LLP is currently investigating uniQure N.V. for potential claims relating to securities fraud. This inquiry focuses on whether the company, along with its senior management, violated federal securities laws or engaged in unlawful business practices.
What Led to the Investigation?
Recently, uniQure made a significant announcement that raised concerns among investors. On November 3, 2025, the company stated that it believes the FDA no longer agrees that data from the Phase I/II studies of AMT-130 could support a Biologics License Application (BLA) submission. This revelation led to a dramatic drop in uniQure’s stock price, which fell by approximately 49.33%, decreasing from $67.69 to $34.29 in just a few days.
Details of the Disclosure
The announcement indicated that the data compared to an external control may not meet the FDA's standards, creating uncertainty about the timeline for submitting the BLA for AMT-130. Such uncertainty typically unsettles investors and can have profound financial implications for a company.
Implications for Investors
Following the stock price decline, many investors are left wondering about their next steps. If you have purchased or acquired uniQure securities and have information that could assist in this investigation, it's crucial to reach out. Knowing your rights and being informed can help mitigate potential losses.
Contact Information
Those interested in learning more about this investigation are encouraged to contact Lauren Molinaro of Kirby McInerney LLP. You can reach out via email to discuss your interests or rights concerning these developments at no cost. The firm specializes in representing shareholders in securities litigation, making them a reliable ally for affected investors.
About Kirby McInerney LLP
Founded in New York, Kirby McInerney LLP is known for its expertise in various legal areas, including securities litigation. The firm has achieved significant recoveries for shareholders in past cases, showcasing their dedication to addressing investor concerns and protecting their interests. For more detailed information, it's advisable to explore their website.
Frequently Asked Questions
What is the investigation about?
The investigation focuses on whether uniQure N.V. and its management may have violated federal securities laws, particularly following a recent significant announcement regarding AMT-130.
Why did uniQure's stock price drop?
uniQure's stock price fell sharply after the company indicated that the FDA no longer supports the data from its Phase I/II studies as satisfactory for a BLA submission.
What should I do if I own uniQure stock?
If you own uniQure stock, you should stay informed about the investigation and consider contacting a legal professional for guidance on your rights.
Who can I contact for more information?
For more information about the investigation, you can contact Lauren Molinaro at Kirby McInerney LLP.
What legal expertise does Kirby McInerney LLP offer?
Kirby McInerney LLP specializes in securities litigation and has a record of recovering significant compensation for shareholders impacted by fraudulent practices.